EBM Technologies Incorporated (TPEX:8409)
20.70
+0.45 (2.22%)
At close: Feb 11, 2026
EBM Technologies Revenue
EBM Technologies had revenue of 113.65M TWD in the quarter ending September 30, 2025, with 135.70% growth. This brings the company's revenue in the last twelve months to 348.42M, up 73.98% year-over-year. In the year 2024, EBM Technologies had annual revenue of 280.95M with 36.29% growth.
Revenue (ttm)
348.42M
Revenue Growth
+73.98%
P/S Ratio
1.90
Revenue / Employee
n/a
Employees
n/a
Market Cap
662.40M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 280.95M | 74.81M | 36.29% |
| Dec 31, 2023 | 206.15M | -177.74M | -46.30% |
| Dec 31, 2022 | 383.88M | 188.95M | 96.93% |
| Dec 31, 2021 | 194.93M | -20.40M | -9.47% |
| Dec 31, 2020 | 215.34M | -19.31M | -8.23% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Lotus Pharmaceutical | 18.66B |
| PharmaEssentia | 13.82B |
| Health & Life | 441.84M |
| Sofiva Genomics | 393.48M |
| BioLASCO Taiwan | 277.12M |
| General Biologicals | 251.38M |
| Bioray Biotech | 230.06M |
| Vectorite Biomedical | 67.90M |